Παρακαλώ χρησιμοποιήστε αυτό το αναγνωριστικό για να παραπέμψετε ή να δημιουργήσετε σύνδεσμο προς αυτό το τεκμήριο:
https://hdl.handle.net/123456789/1108| Τύπος: | Αναρτημένη ανακοίνωση (poster) |
| Τίτλος: | Effect of antidiabetic agents on major adverse cardiovascular events across different age group categories: a meta-analysis of cardiovascular outcome trials |
| Συγγραφέας: | [EL] Μπεκιάρη, Ελένη[EN] Bekiari, Eleni [EL] Καραγιάννης, Θωμάς[EN] Karagiannis, Thomas [EL] Αθανασιάδου, Ελένη[EN] Athanasiadou, Eleni [EL] Τσάπας, Απόστολος[EN] Tsapas, Apostolos |
| Ημερομηνία: | 22/09/2020 |
| Περίληψη: | Background and aims: The effects of antidiabetic drugs on cardiovascular outcomes across different age group categories of patients with type 2 diabetes have not been fully explored. We assessed the potential effect of age on the incidence of cardiovascular outcomes, based on data from cardiovascular outcome trials. Materials and methods: We did a fixed-effect meta-analysis of cardiovascular outcome trials of GLP-1 receptor agonists, SGLT2 inhibitors and DPP-4 inhibitors, synthesising data in subgroups by baseline age (<65 years, ≥65 years, <75 years, and ≥75 years). We calculated hazard ratios (HRs) and 95% confidence intervals (CIs) for the primary outcome of 3-component MACE (major adverse cardiovascular events comprising cardiovascular death, stroke or myocardial infarction). Secondary outcomes included cardiovascular mortality and hospitalisation for heart failure. Results: We included data from 13 randomised, placebo-controlled, cardiovascular outcome trials. In the overall population, GLP-1 receptor agonists and SGLT2 inhibitors reduced MACE by 10-11%, while DPP-4i had a neutral effect (Table). For GLP-1 receptor agonists, in patients <65 years the HR was 0.94 (95% CI 0.87 to 1.02) and in patients ≥65 years it was 0.86 (95% CI 0.80 to 0.92, p for interaction = 0.101). For SGLT2 inhibitors, in patients <65 years the HR was 0.95 (95% CI 0.86 to 1.05) and in patients ≥65 years it was 0.84 (95% CI 0.76 to 0.92, p for interaction = 0.085). For GLP-1 receptor agonists, in patients <75 years the HR for MACE was 0.92 (95% CI 0.85 to 0.99) and in patients ≥75 years it was 0.75 (0.59 to 0.94, p for interaction = 0.056). For SGLT2 inhibitors, in patients <75 years the HR was 0.93 (95% CI 0.85 to 1.02) and in patients ≥75 years it was 0.77 (95% CI 0.60 to 0.99, p for interaction = 0.159). For DPP-4 inhibitors, no differences were evident compared to placebo in any age group categories. Conclusion: Elderly patients with type 2 diabetes, especially those over 75 years of age, are more likely to benefit from the effects of GLP-1 receptor agonists and SGLT2 inhibitors on cardiovascular outcomes. |
| Γλώσσα: | Αγγλικά |
| Σελίδες: | 7 |
| DOI: | 10.1007/s00125-020-05221-5 |
| ISSN: | 0012-186X |
| Θεματική κατηγορία: | [EL] Ιατρική έρευνα και Πειραματική ιατρική[EN] Research and Experimental medicine |
| Κάτοχος πνευματικών δικαιωμάτων: | © The Author(s) 2020 |
| Ηλεκτρονική διεύθυνση του τεκμηρίου στον εκδότη: | https://www.easd.org/media-centre/home.html#!resources/effect-of-antidiabetic-agents-on-major-adverse-cardiovascular-events-across-different-age-group-categories-a-meta-analysis-of-cardiovascular-outcome-trials-fa0788d4-ce12-4a1f-af64-1e2fb9396c67 https://link.springer.com/content/pdf/10.1007/s00125-020-05221-5.pdf |
| Τίτλος πηγής δημοσίευσης: | Diabetologia |
| Τεύχος: | Suppl 1 |
| Τόμος: | 63 |
| Σελίδες τεκμηρίου (στην πηγή): | 944 |
| Όνομα εκδήλωσης: | 56th EASD Annual Meeting of the European Association for the Study of Diabetes |
| Τοποθεσία εκδήλωσης: | Virtual Conference |
| Ημ/νία έναρξης εκδήλωσης: | 21/09/2020 |
| Ημ/νία λήξης εκδήλωσης: | 25/09/2020 |
| Σημειώσεις: | This research was funded by Greece and the European Union (European Social Fund- ESF) through the Operational Programme «Human Resources Development, Education and Lifelong Learning 2014-2020» in the context of the project “Methodological framework for the development and updating of individualized and evidence-based guidelines. A case study on type 2 diabetes mellitus (MIS 5047909)”. 56th EASD Annual Meeting of the European Association for the Study of Diabetes : 21-25 September 2020. Diabetologia. 2020 Sep;63(Suppl 1):1-485. Session: PS 92 Cardiovascular complications in humans through and through. ePoster # 944_PDF |
| Εμφανίζεται στις συλλογές: | Ερευνητικές ομάδες |
Αρχεία σε αυτό το τεκμήριο:
Το πλήρες κείμενο αυτού του τεκμηρίου δεν διατίθεται προς το παρόν από το αποθετήριο